MARKET

UNCY

UNCY

Unicycive Therapeutics Inc
NASDAQ
8.51
+0.34
+4.16%
Closed 19:26 05/13 EDT
OPEN
8.10
PREV CLOSE
8.17
HIGH
8.56
LOW
7.96
VOLUME
669.71K
TURNOVER
0
52 WEEK HIGH
11.00
52 WEEK LOW
3.710
MARKET CAP
227.22M
P/E (TTM)
-5.0912
1D
5D
1M
3M
1Y
5Y
1D
Unicycive Therapeutics publishes corporate presentation on kidney disease drug pipeline
PUBT · 12h ago
Unicycive Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 21h ago
Unicycive Therapeutics Price Target Cut to $37.00/Share From $40.00 by Guggenheim
Dow Jones · 21h ago
Noble Financial Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY)
TipRanks · 21h ago
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $37
Benzinga · 21h ago
Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim
TipRanks · 1d ago
Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)
TipRanks · 1d ago
Unicycive Therapeutics Q1 EPS $(0.54) Misses $(0.51) Estimate
Benzinga · 1d ago
More
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Webull offers Unicycive Therapeutics Inc stock information, including NASDAQ: UNCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UNCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UNCY stock methods without spending real money on the virtual paper trading platform.